Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36410387.
- Also identified by DOI 10.1093/cid/ciac751 and PMC identifier 10200322.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Broadly neutralizing antibodies directed against human immunodeficiency virus (HIV) offer promise as long-acting agents for prevention and treatment of HIV. Progress and challenges are discussed. Lessons may be learned from the development of monoclonal antibodies to treat and prevent COVID-19.
Medical subject headings
- COVID-19
- HIV Infections
- Antineoplastic Agents, Immunological
- HIV-1